Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Dr. Reddy's Laboratories Ltd (RDY : NYSE)

• Company Description    Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India. Number of Employees: 27,811

• Price / Volume Information    Yesterday's Closing Price: $14.04 Daily Weekly Monthly 20 Day Moving Average: 1,013,523 shares Shares Outstanding: 834.94 (millions) Market Capitalization: $11,722.52 (millions) Beta: 0.37 52 Week High: $16.17 52 Week Low: $12.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.71% -0.54% 12 Week -0.92% -2.52% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 8-2-337 ROAD NO.3 BANJARA HILLS - HYDERABAD,K7 500-034 IND ph: 91-40-4900-2900 fax: 91-40-4900-2999 richaperiwal@drreddys.com http://www.drreddys.com

• General Corporate Information    Officers Erez Israeli - Chief Executive Officer K. Satish Reddy - Chairman G.V. Prasad - Co-Chairman M.V. Narasimham - Chief Financial Officer Kalpana Morparia - Director Peer Information Dr. Reddy's Laboratories Ltd (BGMR) Dr. Reddy's Laboratories Ltd (BBIO) Dr. Reddy's Laboratories Ltd (IPAH) Dr. Reddy's Laboratories Ltd (BRL) Dr. Reddy's Laboratories Ltd (BHC) Dr. Reddy's Laboratories Ltd (AKRXQ) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-GENERIC DRG Sector: Medical CUSIP: 256135203 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 09/01/25 Next Expected EPS Date: 01/22/26 Share - Related Items Shares Outstanding: 834.94 Most Recent Split Date: 11.00 (5.00:1) Beta: 0.37 Market Capitalization: $11,722.52 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.51% Current Fiscal Quarter EPS Consensus Estimate: $0.14 Indicated Annual Dividend: $0.07 Current Fiscal Year EPS Consensus Estimate: $0.69 Payout Ratio: 0.09 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: -0.03 Estmated Long-Term EPS Growth Rate: 3.08% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 01/22/26

• Fundamental Ratios P/E Current FY Estimate: 20.45 Trailing 12 Months: 17.33 PEG Ratio: 6.64 Price Ratios Price/Book: 2.87 Price/Cash Flow: 13.60 Price / Sales: 2.95 EPS Growth vs. Year Ago Period: 375.00% vs. Previous Quarter: -5.00% Sales Growth vs. Year Ago Period: 3.66% vs. Previous Quarter: -0.50% ROE 12/31/25 - - 09/30/25 - 17.13 06/30/25 - 17.25 ROA 12/31/25 - - 09/30/25 - 11.57 06/30/25 - 11.63 Current Ratio 12/31/25 - - 09/30/25 - 1.85 06/30/25 - 1.89 Quick Ratio 12/31/25 - - 09/30/25 - 1.35 06/30/25 - 1.36 Operating Margin 12/31/25 - - 09/30/25 - 17.14 06/30/25 - 16.99 Net Margin 12/31/25 - - 09/30/25 - 17.14 06/30/25 - 16.99 Pre-Tax Margin 12/31/25 - - 09/30/25 - 22.14 06/30/25 - 22.77 Book Value 12/31/25 - - 09/30/25 - 4.88 06/30/25 - 4.94 Inventory Turnover 12/31/25 - - 09/30/25 - 2.02 06/30/25 - 1.93 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.03 06/30/25 - 0.01 Debt-to-Capital 12/31/25 - - 09/30/25 - 3.11 06/30/25 - 1.41

Powered by Zacks Investment Research ©